Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International total assets
Total assets on the balance sheet at the end of each period.
Kiniksa Pharmaceuticals International's total assets was $983.24M at Sep 30, 2026. For fiscal 2025 it was $763.63M, up 31.5% from the year before. The highest annual figure on record is $763.63M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $763.63M | +31.5% |
| FY2024 | Dec 31, 2024 | $580.55M | +10.3% |
| FY2023 | Dec 31, 2023 | $526.32M | +14.5% |
| FY2022 | Dec 31, 2022 | $459.67M | +97.5% |
| FY2021 | Dec 31, 2021 | $232.80M | -33.4% |
| FY2020 | Dec 31, 2020 | $349.46M | +37.3% |
| FY2019 | Dec 31, 2019 | $254.53M | -20.9% |
| FY2018 | Dec 31, 2018 | $321.97M | +577.9% |
| FY2017 | Dec 31, 2017 | $47.49M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $983.24M | +38.0% |
| Q2 FY2026 | Jun 30, 2026 | $896.11M | +35.5% |
| Q1 FY2026 | Mar 31, 2026 | $825.28M | +37.7% |
| Q4 FY2025 | Dec 31, 2025 | $763.63M | +31.5% |
| Q3 FY2025 | Sep 30, 2025 | $712.33M | +28.3% |
| Q2 FY2025 | Jun 30, 2025 | $661.15M | +21.9% |
| Q1 FY2025 | Mar 31, 2025 | $599.33M | +15.3% |
| Q4 FY2024 | Dec 31, 2024 | $580.55M | +10.3% |
| Q3 FY2024 | Sep 30, 2024 | $555.30M | +15.0% |
| Q2 FY2024 | Jun 30, 2024 | $542.43M | +12.0% |
| Q1 FY2024 | Mar 31, 2024 | $519.67M | +17.3% |
| Q4 FY2023 | Dec 31, 2023 | $526.32M | +14.5% |
| Q3 FY2023 | Sep 30, 2023 | $483.06M | +5.0% |
| Q2 FY2023 | Jun 30, 2023 | $484.33M | +130.0% |
| Q1 FY2023 | Mar 31, 2023 | $442.86M | +91.7% |
| Q4 FY2022 | Dec 31, 2022 | $459.67M | +97.5% |
| Q3 FY2022 | Sep 30, 2022 | $459.95M | +81.9% |
| Q2 FY2022 | Jun 30, 2022 | $210.58M | -24.6% |
| Q1 FY2022 | Mar 31, 2022 | $230.97M | -25.8% |
| Q4 FY2021 | Dec 31, 2021 | $232.80M | -33.4% |
| Q3 FY2021 | Sep 30, 2021 | $252.86M | -34.2% |
| Q2 FY2021 | Jun 30, 2021 | $279.21M | +2.9% |
| Q1 FY2021 | Mar 31, 2021 | $311.16M | +37.6% |
| Q4 FY2020 | Dec 31, 2020 | $349.46M | +37.3% |
| Q3 FY2020 | Sep 30, 2020 | $384.41M | +36.4% |
| Q2 FY2020 | Jun 30, 2020 | $271.44M | -11.9% |
| Q1 FY2020 | Mar 31, 2020 | $226.11M | -34.7% |
| Q4 FY2019 | Dec 31, 2019 | $254.53M | -20.9% |
| Q3 FY2019 | Sep 30, 2019 | $281.81M | -18.8% |
| Q2 FY2019 | Jun 30, 2019 | $308.14M | -15.6% |
| Q1 FY2019 | Mar 31, 2019 | $346.16M | +628.9% |
| Q4 FY2018 | Dec 31, 2018 | $321.97M | – |
| Q3 FY2018 | Sep 30, 2018 | $347.10M | – |
| Q2 FY2018 | Jun 30, 2018 | $365.13M | – |
| Q4 FY2017 | Dec 31, 2017 | $47.49M | – |
See a number that looks wrong?